[1] ROBERTS TC, LANGER R, WOOD MJA. Advances in oligonucleotide drug delivery[J]. Nat Rev Drug Discov, 2020, 19(10): 673
[2] KIM Y. Drug discovery perspectives of antisense oligonucleotides[J]. Biomol Ther (Seoul), 2023, 31(3): 241
[3] ZHANG C, ZHANG B. RNA therapeutics: updates and future potential[J]. Sci China Life Sci, 2023, 66(1): 12
[4] EGLI M, MANOHARAN M. Chemistry, structure and function of approved oligonucleotide therapeutics[J]. Nucleic Acids Res, 2023, 51(6): 2529
[5] LIU A, CHENG M, ZHOU Y, et al. Bioanalysis of oligonucleotide by LC-MS: effects of ion pairing regents and recent advances in ion-pairing-free analytical strategies[J]. Int J Mol Sci, 2022, 23(24): 15474
[6] SCHÜRCH S. Characterization of nucleic acids by tandem mass spectrometry-the second decade (2004—2013): from DNA to RNA and modified sequences[J]. Mass Spectrom Rev, 2016, 35(4): 483
[7] Clinical Pharmacology and Biopharmaceutics Review(s): Eteplirsen [R/OL]. US FDA, 2016 [2023-04-25]. https://www. accessdata. fda. gov/drugsatfda_docs/nda/2016/206488Orig1s000 ClinPharmR.pdf
[8] Integrated Review: QALSODY [R/OL]. US FDA, 2023 [2023-04-25]. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/215887Orig1s000IntegratedR.pdf
[9] Clinical Pharmacology and Biopharmaceutics Review(s): Casimersen [R/OL]. US FDA,2021 [2023-04-25]. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/213026Orig1s000ClinPharmR.pdf
[10] MULTI-DISCIPLINE REVIEW:patisiran [R]. US FDA, 2018 [2023-04-25]. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210922Orig1s000MultiR.pdf
[11] JO SJ, CHAE SU, LEE CB, et al. Clinical pharmacokinetics of approved RNA therapeutics [J]. Int J Mol Sci, 2023, 24(1): 746
[12] HAEGELE JA, BOYANAPALLI R, GOYAL J. Improvements to hybridization-ligation ELISA methods to overcome bioanalytical challenges posed by novel oligonucleotide therapeutics[J]. Nucleic Acid Ther, 2022, 32(4): 350
[13] WEI X, DAI G, MARCUCCI G, et al. A specific picomolar hybridization-based ELISA assay for the determination of phosphorothioate oligonucleotides in plasma and cellular matrices[J]. Pharm Res, 2006, 23(6): 1251
[14] ROUSSIS SG, CEDILLO I, RENTEL C. Automated determination of early eluting oligonucleotide impurities using ion-pair reversed-phase liquid chromatography high resolution-mass spectrometry[J]. Anal Biochem, 2020, 595: 113623
[15] WANG L. Oligonucleotide bioanalysis: sensitivity versus specificity[J]. Bioanalysis, 2011, 3(12): 1299
[16] DILLEN L, SIPS L, GREWAY T, et al. Quantitative analysis of imetelstat in plasma with LC-MS/MS using solid-phase or hybridization extraction[J]. Bioanalysis, 2017, 9(23): 1859
[17] LI P, GONG Y, KIM J, et al. Hybridization liquid chromatography-tandem mass spectrometry: an alternative bioanalytical method for antisense oligonucleotide quantitation in plasma and tissue samples[J]. Anal Chem, 2020, 92(15): 10548
[18] YUAN L, DUPUIS JF, MEKHSSIAN K. A novel hybridization LC-MS/MS methodology for quantification of siRNA in plasma, CSF and tissue samples[J]. Molecules, 2023, 28(4): 1618
[19] BASIRI B, BARTLETT MG. LC-MS of oligonucleotides: applications in biomedical research[J]. Bioanalysis, 2014, 6(11): 1525
[20] APFFEL A, CHAKEL JA, FISCHER S, et al. Analysis of oligonucleotides by HPLC-electrospray ionization mass spectrometry[J]. Anal Chem, 1997, 69(7): 1320
[21] VAN DONGEN WD, NIESSEN WM. Bioanalytical LC-MS of therapeutic oligonucleotides[J]. Bioanalysis, 2011, 3(5): 541
[22] LI N, EL ZAHAR NM, SAAD JG, et al. Alkylamine ion-pairing reagents and the chromatographic separation of oligonucleotides[J]. J Chromatogr A, 2018, 1580: 110
[23] MACNEILL R, HUTCHINSON T, ACHARYA V, et al. An oligonucleotide bioanalytical LC-SRM methodology entirely liberated from ion-pairing[J]. Bioanalysis, 2019, 11(12): 1157
[24] GONG L, MCCULLAGH JS. Analysis of oligonucleotides by hydrophilic interaction liquid chromatography coupled to negative ion electrospray ionization mass spectrometry[J]. J Chromatogr A, 2011, 1218(32): 5480
[25] HUANG M, XU X, QIU H, et al. Analytical characterization of DNA and RNA oligonucleotides by hydrophilic interaction liquid chromatography-tandem mass spectrometry [J]. J Chromatogr A, 2021, 1648: 462184
[26] STUDZIŃSKA S, ĿOBODZIŃSKI F, BUSZEWSKI B. Application of hydrophilic interaction liquid chromatography coupled with mass spectrometry in the analysis of phosphorothioate oligonucleotides in serum[J]. J Chromatogr B Analyt Technol Biomed Life Sci, 2017, 1040: 282
[27] GOYON A, BLEVINS MS, NAPOLITANO JG, et al. Characterization of antisense oligonucleotide and guide ribonucleic acid diastereomers by hydrophilic interaction liquid chromatography coupled to mass spectrometry [J]. J Chromatogr A, 2023, 1708: 464327
[28] ANAND P, KOLETO M, KANDULA DR, et al. Novel hydrophilic-phase extraction, HILIC and high-resolution MS quantification of an RNA oligonucleotide in plasma[J]. Bioanalysis, 2022, 14(1): 47
[29] LOBUE PA, JORA M, ADDEPALLI B, et al. Oligonucleotide analysis by hydrophilic interaction liquid chromatography-mass spectrometry in the absence of ion-pair reagents[J]. J Chromatogr A, 2019, 1595: 39
[30] EASTER RN, KRÖNING KK, CARUSO JA, et al. Separation and identification of oligonucleotides by hydrophilic interaction liquid chromatography (HILIC)-inductively coupled plasma mass spectrometry (ICPMS)[J]. Analyst, 2010, 135(10): 2560
[31] EASTER R, BARRY C, CARUSO J, et al. Separation and identification of phosphorothioate oligonucleotides by HILIC-ESIMS[J]. Analyt Methods, 2013, 5: 2657
[32] LARDEUX H, GUILLARME D, D'ATRI V. Comprehensive evaluation of zwitterionic hydrophilic liquid chromatography stationary phases for oligonucleotide characterization[J]. J Chromatogr A, 2023, 1690: 463785
[33] GRIFFEY RH, SASMOR H, GREIG MJ. Oligonucleotide charge states in negative ionization electrospray-mass spectrometry are a function of solution ammonium ion concentration[J]. J Am Soc Mass Spectrom, 1997, 8(2): 155
[34] FOUNTAIN KJ, GILAR M, GEBLER JC. Electrospray ionization mass spectrometric analysis of nucleic acids using high-throughput on-line desalting[J]. Rapid Commun Mass Spectrom, 2004, 18(12): 1295
[35] DENG P, CHEN X, ZHANG G, et al. Bioanalysis of an oligonucleotide and its metabolites by liquid chromatography-tandem mass spectrometry[J]. J Pharm Biomed Anal, 2010, 52(4): 571
[36] Clinical Pharmacology and Biopharmaceutics Review(s): Golodirsen [R/OL]. US FDA,2018 [2023-04-25]. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/211970Orig1s000ClinPharmR.pdf
[37] Clinical Pharmacology and Biopharmaceutics Review(s): Viltolarsen [R/OL]. US FDA,2019 [2023-04-25]. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/212154Orig1s000ClinPharmR.pdf
[38] Clinical Pharmacology and Biopharmaceutics Review(s): Defibrotide [R/OL]. US FDA,2016 [2023-04-25]. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/208114 Orig1s000ClinPharmR.pdf
[39] Clinical Pharmacology and Biopharmaceutics Review(s): Mipomersen [R/OL]. US FDA,2013 [2023-04-25]. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/203568Orig1s000ClinPharmR.pdf
[40] Assessment Report: Volanesorsen [R]. EU EMA, 2019, https://www. ema. europa. eu/en/documents/assessment-report/waylivra-epar-public-assessment-report_en.pdf
[41] HUSSER C, KOLLER E, BRINK A, et al. Studying the biotransformation of phosphorothioate-containing oligonucleotide drugs by LC-MS[J]. Methods Mol Biol, 2019, 2036: 307
[42] LIU J, LI J, TRAN C, et al. Oligonucleotide quantification and metabolite profiling by high-resolution and accurate mass spectrometry[J]. Bioanalysis, 2019, 11(21): 1967
[43] SUN Y, NITTA SI, SAITO K, et al. Development of a bioanalytical method for an antisense therapeutic using high-resolution mass spectrometry[J]. Bioanalysis, 2020, 12(24): 1739
[44] RAMANATHAN L, SHEN H. LC-TOF-MS methods to quantify siRNAs and major metabolite in plasma, urine and tissues[J]. Bioanalysis, 2019, 11(21): 1983
[45] AGARWAL S, SIMON AR, GOEL V, et al. Pharmacokinetics and pharmacodynamics of the small interfering ribonucleic acid, givosiran, in patients with acute hepatic porphyria [J]. Clin Pharmacol Ther, 2020, 108(1): 63
[46] Clinical Pharmacology and Biopharmaceutics Review(s): Inclisiran[R/OL]. US FDA, 2020 [2023-04-25]. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/214012Orig1s000ClinPharmR.pdf
[47] INTEGRATED REVIEW: Lumasiran [R]. US FDA, 2020,https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/214103Orig1s000IntegratedR.pdf.
[48] Clinical Pharmacology and Biopharmaceutics Review(s): Vutrisiran [R/OL]. US FDA,2021 [2023-04-25]. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/215515Orig1s 000ClinPharmR.pdf
[49] ROUSSIS SG, CEDILLO I, RENTEL C. Automated determination of early eluting oligonucleotide impurities using ion-pair reversed-phase liquid chromatography high resolution-mass spectrometry[J]. Anal Biochem, 2020, 595: 113623
[50] KAETZKE A, ESCHRICH K. Simultaneous determination of different DNA sequences by mass spectrometric evaluation of Sanger sequencing reactions[J]. Nucleic Acids Res, 2002, 30(21): e117
